Scholars Central

Mini reviewPublished 31 May 2024

Advances in Biologic Therapies for Inflammatory Bowel Disease: Efficacy and Safety Profiles

Authors: Andreas Migdanis

Journal of Inflammatory Bowel Diseases & Disorders

Volume 9 · Issue 2 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Inflammatory Bowel Disease (IBD), encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic inflammatory condition that significantly impacts patients' quality of life. Biologic therapies have revolutionized the management of IBD by targeting specific components of the immune system. This review provides an overview of the latest advances in biologic therapies for IBD, focusing on their efficacy and safety profiles. Recent biologics, including anti-TNF agents, integrin inhibitors and IL-12/23 inhibitors, have shown substantial efficacy in inducing and maintaining remission in IBD patients. However, their use is associated with potential risks, including infections and malignancies. Understanding the benefits and risks of these therapies is crucial for optimizing treatment strategies and improving patient outcomes.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Inflammatory Bowel Diseases & Disorders.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Inflammatory Bowel Diseases & Disorders
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “Andreas Migdanis”